factors for replication. Participation of host cell components is specially required for any of the many HIV-1 gag-encoded functions. Indeed, a variety of Pr55 gag -interacting factors have been identified including actin (1) (2) (3) (4) , calmodulin (5), the motor protein KIF-4 (6), the nuclear transporter karyopherin ␣ (7, 8) , the human nuclear shuttling protein VAN (9) , the translation elongation factor 1-␣ (10), the translation initiation factor 2 (11), the HO3 hystidyl-tRNA synthase (12) , the heat shock protein 70 (13) , and a number of polycomb group proteins (14) . As a consequence, a number of these host cell proteins has been found to be incorporated within HIV-1 virions in addition to virus-encoded components (15, 16) . A specific implication of host cell factors was reported to occur during the late budding stage. Indeed, the Pr55 gag precursor protein is transported to the budding site by an unknown mechanism that most likely utilizes host cell factors and associates with the plasma membrane through cotranslational modifications by the cellular myristyl-S-transferase (17, 18) . The accumulation of the Pr55 gag protein at the plasma membrane then allows its multimerization and is followed by the projection outward of the cell of a spherical budding particle. Recently, the recruitment at the budding site of class E Vps proteins including AIP1/ALIX (19, 20) and the ubiquitin-conjugating enzyme homologue Tsg101 (21) (22) (23) (24) through interactions with the Pr55 gag polyprotein, was reported to be required for the complete release of the viral particle. Interactions with Tsg101, mediated via the PTAP motif identified as the L-domain contained within the p6 gag region, were demonstrated to be enhanced by ubiquitination of the Pr55 gag precursor, suggesting a possible interaction with unknown ubiquitin-conjugating enzymes (22, 25) . Soon after the viral particle pinches off and is released in the extracellular compartment, the viral protease becomes activated and the Pr55 gag polyprotein is cleaved into MAp17 gag , CAp24 gag , NCp7 gag , and p6 gag proteins and p1, p2 spacer peptides. Most of these mature products have also been shown to interact with cellular proteins. As an example, interactions occurring with CAp24 gag have been documented as the mechanism directing incorporation into virions of cyclophilin A (26, 27) , a host cell compound that acts as an uncoating factor and participates to the initial uptake of HIV-1 by target cells (28, 29) . In addition, a number of these Pr55 gag processing products was also suggested to interact with host cell protein kinases as they were found to be phosphorylated. Phosphorylation of the viral MAp17 gag by host cell kinase(s) was found to occur at various steps of the HIV-1 replicative cycle. Indeed, the C-terminal phosphorylation of MAp17 gag protein during and immediately after virus production was proposed to facilitate the dissociation of the viral matrix protein from the cellular membrane (30) . Additional phosphorylation of MAp17 gag by the MAP kinase (MAPK) ERK-2 was proposed to promote membrane dissociation of the reverse transcription complex from the cell membrane at the site of entry, allowing its nuclear translocation (31, 32) . For CAp24 gag , three distinct phosphorylation sites on serine residues were identified (33) . As mutations at these sites were observed to block HIV-1 replicative cycle at an early reverse transcription step, CAp24 gag phosphorylation was proposed to contribute to the early post-entry step by promoting the dissociation of the viral core. Recently, we observed that CAp24 gag interacts with and is phosphorylated by the PKA-C␣ subunit that we found to be incorporated within HIV-1 particles (34) .
More recently, the proline-rich peptide of 52 amino acids termed p6 gag , derived from the C terminus of the Pr55 gag precursor, was reported to be the predominant phosphoprotein of HIV-1 and the contribution of one or several virus-associated kinase(s) was hypothesized (35) . Having demonstrated that the cellular MAPK ERK-2 is specifically incorporated within HIV-1 viral particles (36) , it remained to investigate its role in p6 gag phosphorylation. The present study was thus designed to define the precise contribution of ERK-2 in the phosphorylation of the p6 gag viral protein, to determine critical residues phosphorylated within p6 gag and to elucidate the involvement of p6 gag phosphorylation in the HIV-1 life cycle. As observed from in vitro phosphorylation assays, the p6 gag protein and its p15 gag precursor were found to be phosphorylated by ERK-2 at the level of a single threonine residue (Thr 23 ) located within a conserved MAPK canonical consensus sequence. By analyzing point mutation of the p6 gag protein within a pNL4.3 molecular clone, we observed that substitution of the ERK-2 phosphorylable residue within p6 gag leads to the production of immature viruses unable to separate from the host cell membrane. A faint number of particles released from the producing cells was isolated that were found to display altered morphology and size. Such particles were characterized by incomplete maturation of Pr55 gag precursors accompanied by modifications in the incorporation of reverse transcriptase subunits. As defined from single round infectivity assays performed in the MAGI indicator cell line, Thr 23 mutated virions displayed a reduced infectivity as compared with wild type viruses. Altogether, our data indicate that phosphorylation of a unique site of the p6 gag domain by ERK-2 plays a critical role in the late stage of the HIV-1 life cycle, by contributing to the regulation of viral assembly and/or release.
MATERIALS AND METHODS
Cell Culture and Transfections-Human embryonic kidney 293T cells and MAGI cells (37) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen), 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine. In transfection experiments, cells (3 ϫ 10 5 ) were plated in 6-well culture plates and incubated in the presence of viral DNA diluted in ExGen 500 transfection reagent (Euromedex) at a ratio of 6 units/g of DNA.
Western Blot Analysis-Proteins were separated on a 14% ProSieve® 50 polyacrylamide gel (FMC), then transferred to polyvinylidene difluoride membrane (Immobilon P, Millipore) and revealed by immunoblotting using an anti-CAp24 gag mouse monoclonal antibody (mAb) (ICN), an anti-RT rabbit polyclonal serum (kindly provided by J. L. Darlix, ENS, Lyon, France), or an anti-p6 gag polyclonal serum obtained after immunization of rabbits with GST-p6 gag fusion protein. Anti-MAp17 gag mAb was obtained from Fitzgerald Industries International, Inc., anti-ERK-2 from Santa Cruz Biotechnology, Inc., and anti-GST from Amersham Biosciences. Secondary antibodies conjugated to horseradish peroxidase were revealed by enhanced chemiluminescent detection. Virion Production and Purification-Viral stocks were obtained by transfection of the pNL4.3 HIV-1 molecular clone into 293T cells. Briefly, culture supernatants collected 40 h after transfection were cleared from cellular debris by low-speed centrifugation and filtered on 0.45-m pore size membranes (Millipore). Virions were sedimented by ultracentrifugation through 20% sucrose cushions, at 25,000 rpm for 2 h 30 min at 4°C (SW28 rotor), resuspended in 200 l of phosphatebuffered saline and layered onto the top of an Optiprep velocity gradient (6 -20% (w/v) iodixanol; Abcys SA). Centrifugation was run for 3 h at 26,000 ϫ g at 4°C. Virions were recovered from viruscontaining fractions by additional ultracentrifugation at 95,000 rpm for 5 min at 4°C (TLA100.2 rotor) and lysed. Additional preparation of a highly purified virus (HIV strain HZ 321 , from clade A) obtained by multiple density gradient purification from infected HUT78 supernatant (38) was kindly provided by R. Trauger (Immune Response Corp., Carlsbad, CA).
GST Fusion Proteins, Site-directed Mutagenesis, and Plasmid Production-p6 gag and p15 gag sequences were amplified by PCR experiments from the pNL4.3 proviral DNA with 5Ј-GCGTGGATCCCAGAG-CAGAC, 5Ј-CGGGAATTCTCATTGTGAC and 5Ј-GCGGATCCCAAAG-AAAGACTGTTAAG, 5Ј-CCGAATTCTTATTGTGACGAGGGGTC oligonucleotide primer pairs, respectively, and cloned in-frame into the pGEX 5X.1 expression vector (Amersham Biosciences). Vectors encoding GST-p6 gag mutants, where codons encoding each serine/threonine residue were replaced by sequences encoding an alanine, and the pNL4.3 T23A plasmid were obtained by site-directed mutagenesis using the Gene Editor mutagenesis kit (Promega) and primers are listed in added to the reaction mixture. Phosphorylated products were separated by SDS-PAGE and detected by autoradiography. Two-dimensional Gel Electrophoresis-Purified cell-free virions were analyzed by two-dimensional gel electrophoresis as follows. Virions were solubilized in buffer containing 8 M urea, 2 M thiourea, 4% CHAPS, 65 mM dithioerythritol, 40 mM Tris, and protease inhibitor for 2 h on a wheel. Viral lysates were clarified by centrifugation for 30 min at 20,000 ϫ g. Each sample was added to a rehydratation solution containing 8 M urea, 2 M thiourea, 4% CHAPS, 65 mM dithioerythritol, bromphenol blue, and 1% Pharmalytes pH 3-10 solution (Amersham Biosciences). Immobiline DryStrips, 18 cm, covering a pH range of 3-10 were allowed to rehydrate in the above solution for 4 h without current and then for 12 h under a 30-V current under low viscosity paraffin oil. Isoelectrofocusing was then performed according to the following voltage/time profile: 500 V for 1 h, 1,000 V for 1 h, linearly increasing the gradient to 8,000 V for 2 h, and a final phase of 8,000 V for 40,000 V/h up to a total amount of 50,000 V/h. After the first dimensional run, the individual strip was equilibrated, and then put on the top of the second dimensional gel (15%) with the Hofer Dalt System (Amersham Biosciences) at 150 V/10 gels. Proteins were then transferred onto polyvinylidene difluoride, hybridized with anti-p6 gag serum and horseradish peroxidase-conjugated secondary antibodies, and revealed with ECL reagents.
Viral Infectivity Assays-MAGI indicator cells, which stably express the ␤-galactosidase reporter gene cloned downstream of the HIV-1 LTR promoter, were platted at 8 ϫ 10 4 cells per well, in 24-well plates and exposed to HIV-1 stock solutions normalized according to the CAp24 gag antigen content by enzyme-linked immunosorbent assay (BeckmanCoulter) or to RT activity determined as previously reported (40) . Fortyeight hours post-infection, viral infectivity was monitored by quantification of o-nitrophenyl ␤-D-galactopyranoside hydrolysis from the cell lysates as previously described (41) . ␤-Galactosidase activity evaluated by measuring absorbance at 410 nm was normalized according to total protein content in the cell lysate.
Electron Microscopy Analysis-Transfected 293T cells were processed for thin-layer electron microscopy as follows: 40 h post-transfection, cells were fixed in situ with 2.5% glutaraldehyde in cacodylate buffer (pH 7.4) for 60 min at 4°C. Cells were then post-fixed with 2% osmium tetroxide, washed in cacodylate buffer containing 0.5% tanic acid, and embedded in epon (Embed-812, Electron Microscopy Sciences Inc.). Cell-free virions sedimented by ultracentrifugation for 10 min at 95,000 ϫ g were fixed for 2 h at 4°C in 2.5% glutaraldehyde in cacodylate buffer (pH 7.2). After extensive washes in 0.1 M Sorensen phosphate buffer (pH 7.2), viruses were included in a fibrin clot as described by Charret and Fauré-Fremiet (42) . Viruses were then post-fixed with 2% osmium tetroxide and 0.5% tannic acid, dehydrated, and embedded in epon. Sections were counterstained with uranyl acetate and lead citrate and examined with an Hitachi H7100 transmission electron microscope.
ERK-2 Knock-out Experiments-ERK-2 knock-out was performed by transfection of specific siRNA using the MAPK1(ERK-2) siRNA/siAb assay kit (Dharmacon RNA Technologies). Briefly, 100 pmol of pooled siRNA duplexes specific for the erk-2 sequence or control siRNA duplexes were transfected into 293T cells using the OligofectAMINE transfection reagent at a ratio of 1 l for 20 pmol of siRNA. Inhibition of ERK-2 expression was assayed by immunoblotting of the total cell extracts using anti-ERK-2 mAbs.
RESULTS

p6 gag Protein and Its p15 gag Precursor Are Phosphorylated by ERK-2 Virus-associated Kinase-The p6
gag protein was recently shown to be phosphorylated in vivo and the possible contribution of virus-associated kinase(s) in these phosphorylation events was evoked (35) . To investigate such hypothesis, a lysate of highly purified NL4.3 virions was incubated in the presence of [␥-
32 P]ATP and appropriate kinase buffer. Phosphorylated proteins were separated by SDS-PAGE and revealed by autoradiography. As shown in Fig. 1A , several phosphoproteins evidenced and their nature were investigated by probing the membrane with antibodies raised against HIV-1 proteins. In these experimental conditions, phosphorylated products at 55 and 6 kDa were revealed by using anti-p6 gag serum. This observation indicates that the p6 gag protein and its Pr55 gag precursor are both phosphorylated by host cell protein kinase(s) incorporated within HIV-1 particles. The contribution of host cell contaminating constituents was excluded as similar data were obtained using immunogen grade preparations of HIV strain HZ 321 as a substrate (38) (data not shown). In addition, 24-and 17-kDa phosphorylated proteins were recognized, respectively, with anti-CAp24 gag and anti-MAp17 gag mAbs, specific for processed forms of these proteins. This observation corroborates previous literature data indicating that 
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MAp17 gag and CAp24 gag were phosphorylated by virus-associated kinases (32, 34) . In agreement with our published observations (36) , an additional 42-kDa phosphorylated protein, which we previously identified as the host cell ERK-2 protein kinase incorporated within HIV-1 particles, was also observed from these phosphorylation experiments.
We next investigated the contribution of ERK-2 in p6 gag phosphorylation. GST fusion proteins containing the sequences encoding the p6 gag protein or its p15 gag precursor (see Fig. 1C , lower panel for its composition) were generated and used in an in vitro phosphorylation experiment in the presence of recombinant activated ERK-2 protein kinase (i.e. dually phosphorylated on threonine 183 and tyrosine 185 residues). As shown in Fig. 1B , the GST-p15 gag precursor and GST-p6 gag proteins were found to be phosphorylated. Interestingly, a stronger phosphorylation signal was detected with GST-p15 gag compared with GST-p6 gag . In contrast, no phosphorylation was observed using GST-NCp7 gag or GST-CAp24 gag as a substrate. As previously reported by others (32), ERK-2-dependent phosphorylation of GST-MAp17 gag was observed in our experimental conditions. GST alone and GST-Elk, a natural substrate of ERK-2, are shown as negative and positive controls, respectively. The amount of GST fusion proteins loaded in each lane was ascertained by Western blotting of the membrane with anti-GST mAb. Altogether, our results indicate that the p6 gag protein packaged into virions is phosphorylated and suggest the contribution of ERK-2 virus-associated protein kinase as demonstrated by in vitro experiments. These phosphorylations are susceptible to occur before the complete processing of p6 gag as suggested by the observation of phosphorylated forms of Pr55 gag and p15 gag precursors.
A Single ERK-2 Consensus Sequence within the p6 gag Protein Is Targeted by ERK-2-To define which amino acid residue(s) of p6
gag is/are phosphorylated by the ERK-2 recombinant protein, the presence of the ERK-2 consensus motives was scanned in the total p6 gag sequence. A single canonical ERK-2 motif represented by the (Ser/Thr)-Pro minimal sequence was identified at position 23 of the p6 gag protein encoded by the pNL4.3 molecular clone. According to the compilation of HIV-1 sequences listed in the NIAID data base (43) , this motif was found to be conserved in most HIV-1 consensus sequences with a duplication observed in the consensus from clades M, F, and H (see Table II ). In some cases (clades A and G), the Thr-Pro motif was absent but an equivalent Ser-Pro motif was found immediately beside, suggesting that a strong selection pressure leads to the conservation of an ERK-2 consensus at this site. ERK-2-dependent phosphorylation of the Thr 23 residue was then analyzed in an in vitro phosphorylation assay using synthetic peptides mimicking either wild type (WT) p6
gag spanning residues 12-39, or an equivalent peptide with an alanine replacing the threonine residue at position 23 (T23A) (Fig. 2A) incubated in the presence of recombinant activated ERK-2. As shown in Fig. 2B , phosphorylation of the WT peptide was evidenced from 0.3 to 15 nmol of peptide. In contrast, no phosphorylation signal was observed with equivalent amounts of T23A mutated peptide. These data indicate that residue Thr 23 accounts for ERK-2-dependent phosphorylation of a p6 gag peptide spanning residues 12 to 39. The existence of additional ERK-2 phosphorylation site(s) in p6 gag was next analyzed. A systematic mutational analysis was performed to modify each serine or threonine residue within the p6 gag sequence into an alanine residue. WT or mutated p6 gag proteins were expressed in-frame with the GST sequence and used in an in vitro kinase experiment. As shown in Fig. 2C, p6 gag protein was found to be phosphorylated when incubated with catalytically active ERK-2. ERK-2-dependent phosphorylation of p6 gag was totally abolished only when the Thr 23 residue was mutated into an alanine. No modification of GST-p6 gag phosphorylation was observed when other serine or threonine residues within p6 gag were substituted. Thus, the threonine residue at position 23 within p6 gag appears to be the unique residue of this protein targeted by recombinant activated ERK-2 in vitro.
We next attempted to define the contribution of the Thr 23 residue in in vivo phosphorylation of p6 gag . To this end, a molecular clone of HIV-1 with residue Thr 23 within p6 gag substituted by an alanine (referred as pNL4.3 T23A ) was derived from the pNL4.3 proviral DNA by site-directed mutagenesis as described by Ottman et al. (44) . This mutation induces an asparagine to serine modification in the Pol protein, a substitution that occurs spontaneously in primary HIV-1 isolates, mainly from clades A and G (see the corresponding consensus sequences in Table II ). Purified preparations of NL4.3 and NL4.3 T23A particles were first subjected to a in vitro phosphorylation assay. When the NL4.3 T23A virus lysate was incubated in the presence of [␥-
32 P]ATP, a weak decrease (less that 30%) of p6 gag phosphorylation was observed (data not shown), suggesting that p6 gag might be phosphorylated on multiple residues by kinase distinct from ERK-2. To further investigate this hypothesis, the NL4.3 and NL4.3 T23A samples were then subjected to two-dimensional gel electrophoresis experiments, and p6 gag isoforms were detected by an anti-p6 gag serum. As shown in Fig. 2D , three spots were assigned to wild type forms of virion-associated p6 gag protein that were proposed to correspond to various phosphorylation levels of this protein. gag phosphorylation by ERK-2 in the life cycle of the virus. The ability of the pNL4.3 T23A mutant construct to direct virus particle release was studied in transient transfection experiments. Forty hours after transfection of 293T cells, culture supernatant were collected and RT activity was measured. As shown in Fig. 3A , RT levels produced from the pNL4.3 T23A molecular clone were found to be reproducibly 2.5-3.5 times lower than those observed from the parental pNL4.3 plasmid. This difference was observed for any amount of viral DNA transfected. Similar results were obtained using other cell lines, including the promonocytic THP1 cell line, the H9 CD4 ϩ lymphoblastoid cell line, or HeLa cells (data not shown). These data indicate that substitution by alanine of the ERK-2 phosphorylable Thr 23 residue within 
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gag Proteinp6 gag results in a marked decrease in viral particle release from transfected cells. This decrease is independent of the host cell type.
Interestingly, similar data were obtained when viral particle release was measured from cells with knocked-out ERK-2. Indeed, when viral particle release was assayed from 293T cells expressing the pNL4.3 plasmid transfected with ERK-2-specific siRNA, a significant decrease in viral production, measured as CAp24 gag antigen production (Fig. 3C) or RT levels in culture supernatant (data not shown) was found to be concomitant to the inhibition of ERK-2 expression (Fig. 3B) . Only faint amounts of viral particles are observed that are related to the residual pool of ERK-2 in the host cells (Fig. 3B, right lane) . The observation of similar phenotypes from cells expressing the pNL4.3 T23A molecular clone or knocked-out for ERK-2 expression corroborates in vitro experiments and supports the contribution of ERK-2 in p6 gag phosphorylation in vivo. Release of virions produced from 293T cells transfected with pNL4.3 or pNL4.3 T23A plasmids was next analyzed in thin layer electron microscopy (EM) experiments. A reduced number of viral particles was observed with pNL4.3 T23A -transfected cells, the majority remained attached to the host cell membrane (see Fig. 4A ). Clusters of two or more particles that failed to detach from each other were also observed to be released from these cells. Rare cell-free viral particles were visualized. Among them, a majority displayed a layer of electron dense material underlying the inner leaflet of the membrane and an absence of cone-shaped cores at the center of the particle characteristic of immature virions (Fig. 4B) , whereas a faint proportion of virions with condensed cores corresponding to mature particles was observed. A careful examination of a large number of images indicated that the particle size of NL4.3 T23A cell-free virions differed from that of NL4.3 particles, as plotted in Fig. 4C . The diameter of NL4.3 T23A particles ranged from 87 to 129 nm with a mean diameter of 105.1 Ϯ 10.9 nm and was significantly higher than that of wild type virions (average particle diameter ϭ 81.7 Ϯ 7.4 nm, range ϭ 64 -102 nm). In our experimental conditions, WT particles appear smaller than the expected size of 100 nm because of technical approaches used to embed cell-free virions prior to EM observations. Additional analysis of NL4.3 and NL4.3 T23A virion density was performed by iodixanol velocity gradient centrifugation. Particle sedimentation analysis, assessed by revelation of the CAp24 gag antigen content of each fraction by immunoblotting experiments, revealed that the T23A-mutated particles migrate at a lower density than WT virions (1.087 and 1.099, respectively) with a density shift of 0.012 g/ml from the mutant to the wild type (data not shown). Furthermore, the density distribution of the NL4.3 T23A particles was found to be wider than that of WT virions, ranging from 1.079 to 1.133 and 1.080 to 1.110 g/ml, respectively. The NL4.3 T23A particles thus appeared to be relatively less dense and more heterogeneous than those of NL4.3. Altogether these data indicate that mutation of the Thr 23 phosphorylable residue within the p6 gag protein of HIV-1 interferes with viral particle release from the host cell membrane, leading to the production of low amounts of cell-free virions that differ To determine whether these variations were generated at the level of protein synthesis or incorporation, we next evaluated polyprotein precursors and viral proteins expression in lysates of cells transfected with pNL4.3 or pNL4.3 T23A molecular clones. As shown in Fig. 5A (right panel) processing as well as in the misincorporation of RT subunits. It was previously reported that virus phenotypes including alterations in the pattern of Pr55 gag processing, defects in RT protein incorporation, and immature morphology of viral particles may correlate with an absence or defects of the viral protease activity (37, (45) (46) (47) . To understand the mechanism by which the p6 gag mutation interferes with the viral phenotype, and to determine the precise contribution of the viral protease, we examined the NL4.3 T23A budding in the absence of protease activity. 293T cells were transfected with pNL4.3 and pNL4.3 T23A DNAs and cultured for 24 h in the presence of indinavir sulfate (5 M) (kindly provided by Merck). Cell-free virions were then processed for immunoblot analysis. As shown in Fig. 5B , patterns revealed by an anti-p6 gag serum are similar for NL4.3-and NL4.3 T23A -mutated viruses. Moreover, an accumulation of unprocessed Pr160 gag-pol and Pr55 gag precursors and processing intermediates as p41b associated to viral particles was observed, indicating that the viral processing was abolished. In these experimental conditions, the NL4.3 T23A virion sample produced from protease inhibitor-treated cells contained less Pr55 gag than did the NL4.3 virions produced in similar conditions. As the elimination of protease activity did not allow to recover comparable expression levels of viral precursor proteins for wild type and T23A-mutated virions, our result suggests that differences in viral particle maturation might be linked to a defect in virus release rather than an altered protease activity. In conclusion, the substitution of the Thr 23 residue within p6 gag results in alterations of viral protein maturation and packaging as well as in alteration of virions release.
Contribution of Thr 23 Residue Phosphorylation in HIV-1 Infectivity-Infectivity of NL4.3 and NL4.3 T23A particles was next assessed on the MAGI indicator cell line on the basis of a single round of replication (48) . Virions were purified from supernatants of transfected 293T cells, normalized either for CAp24 gag content or RT activity, and incubated at different infectious concentrations with MAGI indicator cells. Fortyeight h post-infection, viral infection of the cells was monitored by quantification of 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-gal) hydrolysis measured from the cell lysates. As presented in Fig. 6A , infection level of cells exposed to NL4.3 T23A virions was found to be 2.5 to 4 times lower that observed from cells exposed to similar amounts of NL4.3 particles. Such differences were observed at any infectious input tested. Similar data were obtained with infectious supernatants normalized for RT activity (Fig. 6B) . Thus, NL4.3 T23A particles appear to display reduced infectivity as compared with NL4.3 particles. This observation is in agreement with assembly and maturation defects observed from NL4.3 T23A particles. Altogether these data indicate that phosphorylation of the Thr 23 residue within p6 gag contributes to maintain HIV-1 infectivity. gag was found to be phosphorylated by ERK-2, a host cell MAPK that we previously found to be specifically incorporated within HIV-1 particles (36) . This finding further extends the recent observations published by Muller et al. (35) , indicating that within HIV-1 particles, the p6 gag protein is detected under a phosphorylated form and suggesting the contribution of an unknown host cell kinase belonging to the cyclin-dependent/MAPK family.
We show here, from a systematic mutational analysis, that p6 gag phosphorylation by ERK-2 occurs at a unique consensus Thr-Pro phosphorylation site surrounding the Thr 23 residue. This sequence was found to be conserved in most HIV-1 consensus sequences, supporting a possible physiological function. Substitution within the complete pNL4.3 DNA of the sequence encoding the phosphorylable threonine residue at position 23 in p6 gag by an alanine was found to generate viral particles with drastically reduced infectivity. As observed from EM experiments, a majority of NL4.3 T23A virions, that were controlled to display an alteration in virus-associated p6 gag phosphorylation, remained attached to the host cell membrane and frequent clusters of two or more particles that failed to detach from each other were observed. Most of the particles released in the cell supernatant were found to display an immature morphology and showed a significant increase in size as compared with WT virions. Analyzing viral maturation of NL4.3 T23A virions, the persistence of the unprocessed Pr55 gag precursor and misincorporation of viral proteins were observed. Indeed, when the overall levels of gp41 env proteins were normalized, an ϳ8-fold lower level of RT subunits was found in the p6 gag mutant virus compared with the NL4.3 virions. Altogether, such modifications may account for the observed reduction of viral infectious capacity.
Beside the major contribution of ERK-2 in p6 gag phosphorylation, our data highlight the fact that p6 gag is targeted by several host cell kinases. Indeed, in vitro phosphorylation assays performed using preparations of NL4. gag by kinases distinct from ERK-2 remains to be investigated.
In our study, several arguments suggest that the phenotype observed for the NL4.3 T23A mutant particles is not linked to changes in the pol reading frame in a region upstream of the protease. Indeed, the substitution of the Thr 23 residue by an alanine in the pol frame generates a mutation that is frequently encountered in infectious primary isolates of HIV-1. In addition, phenotypes observed are very similar to those generated by p6 gag substitutions that were demonstrated to be silent in Pol (47) . Finally, the fact that comparable levels of cellassociated polyprotein precursors have been detected from cells producing NL4.3 and NL4.3 T23A virions indicates that protein expression and synthesis were not compromised and may rather suggest a defect in the protein incorporation and/or precursors processing. This hypothesis is supported by the fact that, in the context of an inactive protease, a reduced release of NL4.3 T23A particles was still noticed, indicating that the T23A mutation interferes at the level of virus assembly rather than in Pol protein processing.
Interestingly, our findings are reminiscent of phenotypes observed from deletion mutants of the p6 gag L-domain containing protein or when proline residues within the PTAP motif were mutated, resulting in the accumulation of virions at the cell surface in intermediate stages of budding (50 -53) and in the release of a very reduced number of particles that are extremely large in size (54, 55) . However, in contrast to p6 gag mutants previously described in the literature, the T23A mutation failed to produce a complete inhibition of virion separation from the cell membrane. Yet, the proportion of particles released from the cells was significantly reduced as compared with WT virions.
Previous literature reports have proposed that the p6 gag functional role relies both on the presence of the L-domain sequence and on additional determinants located outside of this region within p6 gag , which remain to be identified (56) . We propose from our data that ERK-2-dependent phosphorylation of p6 gag at the level of a single threonine residue is required for proper cell membrane separation, virion-virion detachment, and correct core maturation in this context. Thus, phosphorylation events might contribute to the p6 gag protein late-budding activities.
The precise mechanism by which mutation of ERK-2 phosphorylable residue modifies viral budding remains to be determined. It has been suggested that phosphorylation of p6 gag is likely to occur concomitantly with or after the release of p6 gag at the site of budding at the plasma membrane (35 
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as demonstrated from the present study, is in agreement with this hypothesis. Recent evidences have been obtained that the p6 gag domain of the Pr55 gag plays a predominant role in HIV-1 budding by facilitating efficient virus release through interactions with various cellular proteins, mainly the Tsg101 tumor suppressor protein (21, 22, 24) . This interaction is optimized by p6 gag monoubiquitination as proteasomal blockade profoundly interferes with viral release, morphology, and infectivity of secreted virions by altering the processing of Pr55 gag polyprotein (22, 57) . As approaching phenotypes were observed when the Thr 23 ERK-2-phosphorylable residue of p6 gag was mutated, a relationship may exist between p6 gag phosphorylation, recruitment of ubiquitin, and viral maturation. This hypothesis is supported by the fact that group IV WW domain-containing proteins (a protein family including the E2 ubiquitin ligases) preferentially bind to short sequences with Ser-Pro or Thr-Pro sequences in a phosphorylation-dependent manner (58, 59) . Thus, phosphorylation events may act by facilitating the cooperation between p6 gag and host cell proteins involved in endocytic internalization and endosomal sorting by regulating the recruitment of WW domains of ubiquitin-ligases and consequently the ubiquitin-dependent release of the assembled virions.
In conclusion, we propose that phosphorylation of the p6 gag protein by ERK-2 may contribute in regulating the dynamic of HIV-1 budding/maturation process. The precise machinery of this mechanism remains to be explored. It has been known for years that L-domain containing proteins from several viruses including pp12 protein of Moloney murine leukemia virus, pp24 of Mason-Pfizer monkey virus, and vesicular stomatitis virus M protein are phosphorylated (60 -64) . Although a functional role has been proposed for some of these phosphorylation events, their functional relevance in the viral replicative cycle still remains unclear. We demonstrate here, for the first time, that the phosphorylation of L-domain containing proteins of HIV-1 participates in viral life cycle. As common retroviral budding mechanisms have been suggested, similar processes may exist for viruses other than HIV-1.
